584 related articles for article (PubMed ID: 11978641)
1. Persistent improvement of type 2 diabetes in the Goto-Kakizaki rat model by expansion of the beta-cell mass during the prediabetic period with glucagon-like peptide-1 or exendin-4.
Tourrel C; Bailbe D; Lacorne M; Meile MJ; Kergoat M; Portha B
Diabetes; 2002 May; 51(5):1443-52. PubMed ID: 11978641
[TBL] [Abstract][Full Text] [Related]
2. Glucagon-like peptide-1 and exendin-4 stimulate beta-cell neogenesis in streptozotocin-treated newborn rats resulting in persistently improved glucose homeostasis at adult age.
Tourrel C; Bailbé D; Meile MJ; Kergoat M; Portha B
Diabetes; 2001 Jul; 50(7):1562-70. PubMed ID: 11423477
[TBL] [Abstract][Full Text] [Related]
3. Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro.
Parkes DG; Pittner R; Jodka C; Smith P; Young A
Metabolism; 2001 May; 50(5):583-9. PubMed ID: 11319721
[TBL] [Abstract][Full Text] [Related]
4. Impaired development of pancreatic beta-cell mass is a primary event during the progression to diabetes in the GK rat.
Movassat J; Saulnier C; Serradas P; Portha B
Diabetologia; 1997 Aug; 40(8):916-25. PubMed ID: 9267986
[TBL] [Abstract][Full Text] [Related]
5. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats.
Xu G; Stoffers DA; Habener JF; Bonner-Weir S
Diabetes; 1999 Dec; 48(12):2270-6. PubMed ID: 10580413
[TBL] [Abstract][Full Text] [Related]
6. Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats.
Perfetti R; Zhou J; Doyle ME; Egan JM
Endocrinology; 2000 Dec; 141(12):4600-5. PubMed ID: 11108273
[TBL] [Abstract][Full Text] [Related]
7. Once daily injection of exendin-4 to diabetic mice achieves long-term beneficial effects on blood glucose concentrations.
Greig NH; Holloway HW; De Ore KA; Jani D; Wang Y; Zhou J; Garant MJ; Egan JM
Diabetologia; 1999 Jan; 42(1):45-50. PubMed ID: 10027577
[TBL] [Abstract][Full Text] [Related]
8. Glucagon-like peptide I enhances the insulinotropic effect of glibenclamide in NIDDM patients and in the perfused rat pancreas.
Gutniak MK; Juntti-Berggren L; Hellström PM; Guenifi A; Holst JJ; Efendic S
Diabetes Care; 1996 Aug; 19(8):857-63. PubMed ID: 8842604
[TBL] [Abstract][Full Text] [Related]
9. Long-term exendin-4 treatment delays natural deterioration of glycaemic control in diabetic Goto-Kakizaki rats.
Simonsen L; Pilgaard S; Orskov C; Hartmann B; Holst JJ; Deacon CF
Diabetes Obes Metab; 2009 Sep; 11(9):884-90. PubMed ID: 19508463
[TBL] [Abstract][Full Text] [Related]
10. Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats.
Farilla L; Hui H; Bertolotto C; Kang E; Bulotta A; Di Mario U; Perfetti R
Endocrinology; 2002 Nov; 143(11):4397-408. PubMed ID: 12399437
[TBL] [Abstract][Full Text] [Related]
11. Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes.
Nielsen LL; Young AA; Parkes DG
Regul Pept; 2004 Feb; 117(2):77-88. PubMed ID: 14700743
[TBL] [Abstract][Full Text] [Related]
12. Accelerated loss of islet beta cells in sucrose-fed Goto-Kakizaki rats, a genetic model of non-insulin-dependent diabetes mellitus.
Koyama M; Wada R; Sakuraba H; Mizukami H; Yagihashi S
Am J Pathol; 1998 Aug; 153(2):537-45. PubMed ID: 9708813
[TBL] [Abstract][Full Text] [Related]
13. Glucagon-like peptide-1 and islet lipolysis.
Sörhede Winzell M; Ahrén B
Horm Metab Res; 2004; 36(11-12):795-803. PubMed ID: 15655711
[TBL] [Abstract][Full Text] [Related]
14. Duodenal-jejunal bypass protects GK rats from {beta}-cell loss and aggravation of hyperglycemia and increases enteroendocrine cells coexpressing GIP and GLP-1.
Speck M; Cho YM; Asadi A; Rubino F; Kieffer TJ
Am J Physiol Endocrinol Metab; 2011 May; 300(5):E923-32. PubMed ID: 21304061
[TBL] [Abstract][Full Text] [Related]
15. Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis.
Li Y; Hansotia T; Yusta B; Ris F; Halban PA; Drucker DJ
J Biol Chem; 2003 Jan; 278(1):471-8. PubMed ID: 12409292
[TBL] [Abstract][Full Text] [Related]
16. Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats.
Pospisilik JA; Martin J; Doty T; Ehses JA; Pamir N; Lynn FC; Piteau S; Demuth HU; McIntosh CH; Pederson RA
Diabetes; 2003 Mar; 52(3):741-50. PubMed ID: 12606516
[TBL] [Abstract][Full Text] [Related]
17. Is defective pancreatic beta-cell mass environmentally programmed in Goto-Kakizaki rat model of type 2 diabetes?: insights from crossbreeding studies during suckling period.
Calderari S; Gangnerau MN; Meile MJ; Portha B; Serradas P
Pancreas; 2006 Nov; 33(4):412-7. PubMed ID: 17079948
[TBL] [Abstract][Full Text] [Related]
18. Glucagon-like peptide-1.
Doyle ME; Egan JM
Recent Prog Horm Res; 2001; 56():377-99. PubMed ID: 11237222
[TBL] [Abstract][Full Text] [Related]
19. GLP-1, exendin-4 and C-peptide regulate pancreatic islet microcirculation, insulin secretion and glucose tolerance in rats.
Wu L; Olverling A; Huang Z; Jansson L; Chao H; Gao X; Sjöholm Å
Clin Sci (Lond); 2012 Apr; 122(8):375-84. PubMed ID: 22054347
[TBL] [Abstract][Full Text] [Related]
20. Effects of glucagon-like peptide-1 and exendins on kinase activity, glucose transport and lipid metabolism in adipocytes from normal and type-2 diabetic rats.
Sancho V; Trigo MV; González N; Valverde I; Malaisse WJ; Villanueva-Peñacarrillo ML
J Mol Endocrinol; 2005 Aug; 35(1):27-38. PubMed ID: 16087719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
